FOUNDATIONONE®LIQUID CDx

PATIENT
Ko, Chi-Lin

TUMOR TYPE
Lung adenocarcinoma
COUNTRY CODE
TW

REPORT DATE
07 June 2023
ORDERED TEST #
ORD-1642958-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Lung adenocarcinoma
NAME Ko, Chi-Lin
DATE OF BIRTH 28 February 1960
SEX Male
MEDICAL RECORD # 48487554

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID CLK 2/28/1960
SPECIMEN TYPE Blood
DATE OF COLLECTION 30 May 2023
SPECIMEN RECEIVED 01 June 2023

Biomarker Findings

Blood Tumor Mutational Burden - 4 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

NF2 E112fs*12
CDKN2A/B CDKN2A rearrangement intron 2
STAG2 splice site 3054-2A>T

Report Highlights

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 9)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 4 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Elevated Tumor Fraction	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. There is higher sensitivity for identifying genomic alterations and a lower risk of false negative results in specimens with elevated tumor fraction; the positive percent agreement observed between liquid and tissue for defined short variants is ≥ 90% (Li et al., 2021; AACR Abstract 2231) (see Biomarker Findings section).**

GENOMIC FINDINGS		VAF%	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
NF2 -	E112fs*12	4.2%	None	None
10 Trials see p. 9				

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2A rearrangement intron 2 ..... p. 7
STAG2 - splice site 3054-2A>T ..... p. 8

Electronically signed by Douglas A. Mata, MD, MPH | 07 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.



HISTORIC PATIENT FINDINGS		ORD-1642958-01 VAF%
Blood Tumor Mutational Burden		4 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		11%
NF2	● E112fs*12	4.2%
CDKN2A/B	CDKN2A rearrangement intron 2	4.8%
STAG2	● splice site 3054-2A>T	15.9%

IMPORTANT NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. Variants reported for prior time points reflect reporting practices at the time of the historical test(s). Changes in variant reporting nomenclature, classification, or handling may result in the appearance of discrepancies across time points. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable or reportable variants may become VUS.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Please note that other aspects of this table may have changed from the previous version to reflect the most up-to-date reporting information.

BIOMARKER

Blood Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-3], anti-PD-1[3-4], anti-PD-1/CTLA4 therapies[5-6] , anti-PD-L1/CTLA4 therapies[7-10]. A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor[5]. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb[1,8-10]. In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[11]. In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[7].

FREQUENCY & PROGNOSIS

NSCLC harbors a median bTMB of 16.8 Muts/Mb (range 1.9-52.5 Muts/Mb)[4]. Retrospective analysis of the Phase 3 OAK and Phase 2 POPLAR trials for patients with advanced or metastatic non-small cell lung cancer (NSCLC) reported that bTMB ≥7 Muts/Mb was associated with shorter PFS (2.8 vs. 4.2 months) and OS (7.4 vs. 11.9 months) compared with bTMB <7 Muts/Mb for patients treated with docetaxel[12]. In one study of advanced NSCLC in China, bTMB ≥6 Muts/Mb was associated with decreased PFS (10 vs. 18 months) and OS (11 vs. 25 months) compared with bTMB <6 Muts/Mb for patients treated with platinum-based chemotherapy[13]. A meta-analysis of 19 studies of immune checkpoint inhibitor-treated NSCLC (n = 2,315 patients) demonstrated that high TMB predicted a significantly longer OS than low TMB (HR = 0.70), and within the high TMB group, immunotherapy was associated with an improved PFS (HR = 0.62, P<0.001), OS (HR = 0.67, P<0.001) and a higher response rate (OR = 2.35, P<0.001) compared to chemotherapy[14]. In contrast, a large study of Chinese patients with untreated lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)[15]. Another study of patients with NSCLC treated with EGFR inhibitors or platinum doublet chemotherapy found elevated TMB to be correlated with poorer prognosis, as well as finding lower TMB in combination with PD-L1 negative status to be significantly associated with longer median survival in patients with lung adenocarcinoma[16]. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC[16-17].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[18-19] and cigarette smoke in lung cancer[20-21], treatment with temozolomide-based chemotherapy in glioma[22-23], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[24-28], and microsatellite instability (MSI)[24,27-28]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-2,4]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

Electronically signed by Douglas A. Mata, MD, MPH | 07 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[29-34].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[35]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[36], Ewing sarcoma and osteosarcoma[37], prostate cancer[32], breast cancer[38], leiomyosarcoma[39], esophageal cancer[40], colorectal cancer[41], and gastrointestinal cancer[42].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[43], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[44-45].

GENE

NF2

ALTERATION
E112fs*12

HGVS VARIANT
NM_000268.3:c.334_350del (p.E112lfs*12)

VARIANT CHROMOSOMAL POSITION
chr22:30035171-30035188

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Loss or inactivation of NF2 may also predict sensitivity to FAK inhibitors based on clinical data in mesothelioma[46] and meningioma[47] and strong preclinical data[48-50]. NF2 inactivating alterations may indicate sensitivity to mTOR inhibitors[51-54]. Two case studies reported clinical benefit for patients with NF2-mutated cancers, including urothelial carcinoma[55] and metaplastic breast cancer[56-57] treated with everolimus and temsirolimus, respectively. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of the MEK inhibitor trametinib and the MTOR inhibitor everolimus in a Phase 1b trial for solid tumors[58], a retrospective study for patients with solid tumors who were heavily pretreated reported tolerable regimens of the combination for 74% (23/31) of patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[59]. A Phase 1 trial of YAP/TEAD inhibitor VT3989 for patients with NF2-mutated tumors or mesothelioma reported 2 PRs for patients with heavily pretreated mesothelioma and 1 PR for a patient with heavily pretreated spindle cell sarcoma[60].

FREQUENCY & PROGNOSIS

NF2 mutation or homozygous loss is not common in lung non-small cell lung cancer (NSCLC) and has been reported in 1% of squamous cell carcinoma and adenocarcinoma samples analyzed in the TCGA datasets[61-62]. The prognostic significance of NF2 mutation in lung carcinomas has not been established, although one study associated acquired NF2 inactivation with resistance to afatinib plus cetuximab in EGFR-mutated lung adenocarcinoma[63].

FINDING SUMMARY

Merlin, encoded by NF2, coordinates cell contact with growth signals; the inactivation of Merlin disrupts this mechanism and can lead to unrestrained growth despite cell contact[64]. Alterations such as seen here may disrupt NF2 function or expression[65-71].

POTENTIAL GERMLINE IMPLICATIONS

Heterozygous germline NF2 loss or inactivation is associated with neurofibromatosis type 2, which results in the development of vestibular schwannomas, meningiomas, ependymomas, and ocular disturbances[72-74]. Prevalence for this disorder in the general population is estimated to be 1:25,000[74]. In the appropriate clinical context, germline testing of NF2 is recommended.

GENE

CDKN2A/B

ALTERATION
CDKN2A rearrangement intron 2

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[75-78]. Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib[79] and palbociclib treatment[80-81]. However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[82-88]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[89-90], the clinical relevance of p14ARF as a predictive biomarker is not clear.

FREQUENCY & PROGNOSIS

CDKN2A/B loss and CDKN2A mutation have been reported in approximately 19% and 4% of lung adenocarcinomas, respectively[61]. CDKN2A/B loss and CDKN2A mutation have been reported in 26% and 17% of lung squamous cell carcinoma (SCC) samples analyzed in the TCGA dataset, respectively[62]. Loss of p16INK4a protein expression, through CDKN2A mutation, homozygous deletion, or promoter methylation, has been described in 49-68% of non-small cell lung cancer (NSCLC) samples, whereas low p14ARF protein expression has been detected in 21-72% of NSCLC samples[62,91-96]. Loss of p16INK4a protein as well as CDKN2A promoter hypermethylation correlate with poor survival in patients with NSCLC[93,97-99].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[100-101]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[92,102]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[103-104]. One or more alterations observed here are predicted to result in p16INK4a loss of function[105-126]. One or more alterations seen here are predicted to result in p14ARF loss of function[109,126-129].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[130]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[131-132]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[133-135]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[136-138]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

GENE

STAG2

ALTERATION
splice site 3054-2A>T

HGVS VARIANT
NM_006603.4:c.3054-2A>T (p.?)

VARIANT CHROMOSOMAL POSITION
chrX:123220395

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies that directly target STAG2 alterations. Preclinical studies suggest that STAG2 loss of function may increase sensitivity to PARP inhibitors[139-140] or oxaliplatin[141]. Preclinical and limited clinical evidence suggests that STAG2 inactivation may reduce sensitivity to BRAF and MEK inhibitors[142].

FREQUENCY & PROGNOSIS

STAG2 mutations are most prevalent in urothelial carcinoma (11-35%)[143-148] and Ewing sarcoma (13-22%)[149-150] and are rare in other tumor types[151]. Reports conflict regarding the prognostic significance of STAG2 alterations or loss in urothelial cancer, potentially due to differences between muscle-invasive and non-muscle-invasive disease, level of STAG2 protein expression, and outcome measurements[144-146,152-154]. For patients with Ewing sarcoma, co-occurrence of STAG2 and TP53 mutations is associated with decreased OS, while STAG2 mutations alone did not associate with poor prognosis[149-150]. For patients with pancreatic ductal adenocarcinoma, loss of STAG2 significantly associates with decreased OS but also with survival benefit from adjuvant chemotherapy[141].

FINDING SUMMARY

STAG2 is a tumor suppressor that encodes a core subunit of the cohesin complex[141,155]. Inactivation by truncating mutation, deletion, or impaired protein expression may promote tumorigenesis via increased aneuploidy[143,145,156] and/or altered transcriptional regulation[144,146,157-159].

Electronically signed by Douglas A. Mata, MD, MPH | 07 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
NF2

ALTERATION
E112fs*12

RATIONALE
Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT03334617

PHASE 2

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.

TARGETS
PD-L1, PARP, mTORC1, mTORC2, ATR, CD73, STAT3

LOCATIONS: Seoul (Korea, Republic of), Berlin (Germany), Wien (Austria), Großhansdorf (Germany), Salzburg (Austria), Innsbruck (Austria), Esslingen a.N. (Germany), Heidelberg (Germany), Edmonton (Canada), Paris (France)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)

NCT05036226

PHASE 1/2

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

TARGETS
DDR2, ABL, SRC, KIT, mTOR

LOCATIONS: South Carolina

NCT01737502

PHASE 1/2

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

TARGETS
mTOR

LOCATIONS: Florida

NCT04250545

PHASE 1

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

TARGETS
mTORC1, mTORC2, GLS

LOCATIONS: California, New York

NCT01582191

PHASE 1

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

TARGETS
mTOR, EGFR, SRC, RET, VEGFRs

LOCATIONS: Texas

NCT03203525

PHASE 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

TARGETS
VEGFA, mTOR

LOCATIONS: Texas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AMER1 (FAM123B OR WTX)
NM_152424.3: c.1472G>A
(p.R491H)
chrX:63411695

DNMT3A
NM_022552.3: c.2281A>G
(p.M761V)
chr2:25463212

DOT1L
NM_032482.2:
c.1765_1772del
(p.N589Afs*75)
chr19:2213951-2213959

FANCA
NM_000135.2: c.3713G>A
(p.R1238K)
chr16:89809260

KMT2A (MLL)
NM_005933.3: c.10318G>A
(p.A3440T)
chr11:118376934

MST1R
NM_002447.2: c.2917G>A
(p.A973T)
chr3:49933193

NTRK1
NM_002529.3: c.2127C>A
(p.D709E)
chr1:156849871

PTCH1
NM_000264.3: c.3793G>A
(p.A1265T)
chr9:98211362

SETD2
NM_014159.6: c.4622A>G
(p.N1541S)
chr3:47155459

ZNF217
NM_006526.2: c.1645G>A
(p.A549T)
chr20:52193658

Electronically signed by Douglas A. Mata, MD, MPH | 07 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1642958-01

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B or WTX)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	***CCND1***	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*	***CD274*** **(PD-L1)**	*CDC73*
CDH1	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*	***CDKN2A***	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2 **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15, **24-27**	*EMSY* (C11orf30)	*EP300*	*EPHA3*
EPHB1	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***	***ESR1*** **Exons 4-8**
*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FANCA*	*FANCC*	*FANCG*
FANCL	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*	*FGF23*	*FGF3*
FGF4	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*	*FLCN*	*FLT1*
FLT3 **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*	*GID4* (C17orf39)	***GNA11*** **Exons 4, 5**
GNA13	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3-3A* (H3F3A)	*HDAC1*	*HGF*	*HNF1A*
HRAS **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*	*INPP4B*
IRF2	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*	*KDM5C*
KDM6A	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)	***KRAS***

Electronically signed by Douglas A. Mata, MD, MPH | 07 June 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *) ; 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

LTK	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*	*MAPK1*
MCL1	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***	*MITF*
MKNK1	*MLH1*	***MPL*** **Exon 10**	*MRE11* (MRE11A)	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*	*MTAP*
MTOR **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*	***NF1***
NF2	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**	***NRAS*** **Exons 2, 3**
NSD2 (WHSC1 or MMSET)	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARP1	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**	***PDGFRB*** **Exons 12-21, 23**
PDK1	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*	*POLD1*
POLE	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PRKN* (PARK2)	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C* (FAM46C)	*TERC** ncRNA	***TERT**** **Promoter**
TET2	*TGFBR2*	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*
TYRO3	*U2AF1*	***VEGFA***	*VHL*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
Blood Tumor Mutational Burden (bTMB)
Tumor Fraction

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*,

KMT2D (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.9.0

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
4. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Chen EX, et al. JAMA Oncol (2020) pmid: 32379280
8. Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377
9. Si H, et al. Clin Cancer Res (2021) pmid: 33355200
10. Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700
11. Li et al., 2020; ASCO Abstract 6511
12. Nie W, et al. J Natl Compr Canc Netw (2020) pmid: 32380463
13. Ma Y, et al. Front Oncol (2021) pmid: 34055609
14. Meng G, et al. PLoS One (2022) pmid: 35113949
15. Xiao D, et al. Oncotarget (2016) pmid: 27009843
16. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
17. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
18. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
19. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
20. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
21. Rizvi NA, et al. Science (2015) pmid: 25765070
22. Johnson BE, et al. Science (2014) pmid: 24336570
23. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
24. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
25. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
26. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
27. Nature (2012) pmid: 22810696
28. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
29. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
30. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
31. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
32. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
33. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
34. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
35. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
36. Lapin M, et al. J Transl Med (2018) pmid: 30400802
37. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
38. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
39. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
40. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
41. Fan G, et al. PLoS ONE (2017) pmid: 28187169
42. Vu et al., 2020; DOI: 10.1200/PO.19.00204
43. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
44. Zhang EW, et al. Cancer (2020) pmid: 32757294
45. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
46. Soria JC, et al. Ann. Oncol. (2016) pmid: 27733373
47. Brastianos et al., 2020; ASCO Abstract 2502
48. Poulikakos PI, et al. Oncogene (2006) pmid: 16652148
49. Shapiro IM, et al. Sci Transl Med (2014) pmid: 24848258
50. Shah NR, et al. Gynecol. Oncol. (2014) pmid: 24786638
51. López-Lago MA, et al. Mol. Cell. Biol. (2009) pmid: 19451229
52. James MF, et al. Mol. Cell. Biol. (2009) pmid: 19451225
53. Pachow D, et al. Clin. Cancer Res. (2013) pmid: 23406776
54. Iyer G, et al. Science (2012) pmid: 22923433
55. Ali SM, et al. Eur. Urol. (2015) pmid: 25630452
56. Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784
57. Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190
58. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
59. Patterson et al., 2018; AACR Abstract 3891
60. Yap et al., 2023; AACR Abstract CT006
61. Nature (2014) pmid: 25079552
62. Nature (2012) pmid: 22960745
63. Pirazzoli V, et al. Cell Rep (2014) pmid: 24813888
64. Curto M, et al. Br. J. Cancer (2008) pmid: 17971776
65. Laulajainen M, et al. J. Cell. Mol. Med. (2012) pmid: 22325036
66. Lallemand D, et al. J. Cell. Sci. (2009) pmid: 19910496
67. Sherman L, et al. Oncogene (1997) pmid: 9395247
68. Li W, et al. EMBO Rep. (2012) pmid: 22482125
69. Manetti ME, et al. Biol Open (2012) pmid: 23213372
70. Stokowski RP, et al. Am. J. Hum. Genet. (2000) pmid: 10712203
71. Mani T, et al. Mol. Cell. Biol. (2011) pmid: 21402777
72. Evans GR, et al. Adv. Otorhinolaryngol. (2011) pmid: 21358190
73. Lu-Emerson C, et al. Rev Neurol Dis (2009) pmid: 19898272
74. Asthagiri AR, et al. Lancet (2009) pmid: 19476995
75. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
76. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
77. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
78. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
79. Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829
80. Elvin JA, et al. Oncologist (2017) pmid: 28283584
81. Gao J, et al. Curr Oncol (2015) pmid: 26715889
82. Gopalan et al., 2014; ASCO Abstract 8077
83. Peguero et al., 2016; ASCO Abstract 2528
84. Konecny et al., 2016; ASCO Abstract 5557
85. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
86. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
87. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
88. Johnson DB, et al. Oncologist (2014) pmid: 24797823
89. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
90. Gamble LD, et al. Oncogene (2012) pmid: 21725357
91. Doxtader EE, et al. Hum. Pathol. (2012) pmid: 21840041
92. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
93. Kratzke RA, et al. Cancer Res. (1996) pmid: 8758904
94. Lee JU, et al. Tuberc Respir Dis (Seoul) (2012) pmid: 23101020
95. Cortot AB, et al. Clin Lung Cancer (2014) pmid: 24169260
96. Mounawar M, et al. Cancer Res. (2007) pmid: 17575133
97. Kawabuchi B, et al. Int. J. Cancer (1999) pmid: 9988232
98. Xing XB, et al. PLoS ONE (2013) pmid: 23805242
99. Lou-Qian Z, et al. PLoS ONE (2013) pmid: 23372805
100. Quelle DE, et al. Cell (1995) pmid: 8521522
101. Mutat. Res. (2005) pmid: 15878778
102. Oncogene (1999) pmid: 10498883
103. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
104. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
105. Ruas M, et al. Oncogene (1999) pmid: 10498896
106. Jones R, et al. Cancer Res. (2007) pmid: 17909018
107. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
108. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
109. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
110. Gombart AF, et al. Leukemia (1997) pmid: 9324288
111. Yang R, et al. Cancer Res. (1995) pmid: 7780957
112. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
113. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
114. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
115. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
116. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
117. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
118. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
119. Koh J, et al. Nature (1995) pmid: 7777061
120. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
121. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
122. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
123. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
124. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
125. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
126. Rutter JL, et al. Oncogene (2003) pmid: 12853981
127. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
128. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
129. Zhang Y, et al. Cell (1998) pmid: 9529249
130. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
131. Adv Exp Med Biol (2010) pmid: 20687502
132. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
133. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
134. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
135. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
136. Kaufman DK, et al. Neurology (1993) pmid: 8414022
137. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
138. Chan AK, et al. Clin Neuropathol () pmid: 28699883
139. Subramaniam A, et al. Haematologica (2022) pmid: 35638550
140. Bailey ML, et al. Mol. Cancer Ther. (2014) pmid: 24356817
141. Evers L, et al. Genome Med (2014) pmid: 24484537
142. Shen CH, et al. Nat. Med. (2016) pmid: 27500726
143. Solomon DA, et al. Nat. Genet. (2013) pmid: 24121789
144. Balbás-Martínez C, et al. Nat. Genet. (2013) pmid: 24121791
145. Guo G, et al. Nat. Genet. (2013) pmid: 24121792
146. Taylor CF, et al. Hum. Mol. Genet. (2014) pmid: 24270882
147. Nature (2014) pmid: 24476821
148. Hoang ML, et al. Sci Transl Med (2013) pmid: 23926200
149. Tirode F, et al. Cancer Discov (2014) pmid: 25223734
150. Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205
151. Zehir A, et al. Nat. Med. (2017) pmid: 28481359
152. Athans S, et al. Cancer Res Commun (2022) pmid: 36275363
153. Gordon NS, et al. Eur Urol Open Sci (2022) pmid: 35495284
154. Taber A, et al. Urol Oncol (2021) pmid: 33712344
155. Richart L, et al. Nucleic Acids Res (2021) pmid:

34648034
156. Solomon DA, et al. Science (2011) pmid: 21852505
157. Thota S, et al. Blood (2014) pmid: 25006131
158. Kon A, et al. Nat. Genet. (2013) pmid: 23955599
159. Solomon DA, et al. BMB Rep (2014) pmid: 24856830